Bg pattern

LYFNUA 45 mg FILM-COATED TABLETS

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use LYFNUA 45 mg FILM-COATED TABLETS

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show translation

Introducción

Prospecto: información para el paciente

Lyfnua 45mg comprimidos recubiertos con película

gefapixant

Este medicamento está sujeto a seguimiento adicional, lo que agilizará la detección de nueva información sobre su seguridad. Puede contribuir comunicando los efectos adversos que pudiera usted tener. La parte final de la sección 4 incluye información sobre cómo comunicar estos efectos adversos.

Lea todo el prospecto detenidamente antes de empezar a tomar este medicamento, porque contiene información importante para usted.

  • Conserve este prospecto, ya que puede tener que volver a leerlo.
  • Si tiene alguna duda, consulte a su médico o farmacéutico.
  • Este medicamento se le ha recetado solamente a usted, y no debe dárselo a otras personas aunque tengan los mismos síntomas que usted, ya que puede perjudicarles.
  • Si experimenta efectos adversos, consulte a su médico o farmacéutico, incluso si se trata de efectos adversos que no aparecen en este prospecto. Ver sección 4.

Contenido del prospecto

  1. Qué es Lyfnua y para qué se utiliza
  2. Qué necesita saber antes de empezar a tomar Lyfnua
  3. Cómo tomar Lyfnua
  4. Posibles efectos adversos
  5. Conservación de Lyfnua
  6. Contenido del envase e información adicional

1. Qué es Lyfnua y para qué se utiliza

Lyfnua contiene el principio activo gefapixant.

Lyfnua es un medicamento que se utiliza en adultos para la tos crónica (tos que dura más de 8 semanas) y:

  • la tos no desaparece incluso después de utilizar otros medicamentos o
  • se desconoce la razón de la tos.

El principio activo de Lyfnua, gefapixant, bloquea la acción de los nervios que provocan la tos anormal.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. Qué necesita saber antes de empezar a tomar Lyfnua

No tome Lyfnua

  • sí es alérgicoa gefapixant o a alguno de los demás componentes de este medicamento (incluidos en la sección 6).

Advertencias y precauciones

Consulte a su médico o farmacéutico antes de empezar a tomar y mientras esté tomando Lyfnua si:

  • es alérgicoa medicamentos que contienen sulfonamida
  • tiene apnea del sueño– en la que su respiración se detiene y vuelve a empezar mientras duerme
  • desarrolla una infección aguda del pulmón/sistema respiratorio inferior (por ejemplo, neumonía o bronquitis)
  • percibe un cambio en el sabor de las cosas, pérdida del gustoo menos capacidad para saborear, que continúa incluso después de dejar de tomar Lyfnua.

Niños y adolescentes

No dé este medicamento a niños y adolescentes menores de 18 años de edad. Esto es porque no se ha estudiado en este grupo de edad.

Otros medicamentos y Lyfnua

Informe a su médico o farmacéutico si está tomando, ha tomado recientemente o pudiera tener que tomar cualquier otro medicamento.

Embarazo y lactancia

Se desconoce si Lyfnua pueden dañar al feto. Por lo tanto, es mejor evitar el uso de Lyfnua si está embarazada.

Si está embarazada, cree que podría estar embarazada o tiene intención de quedarse embarazada, consulte a su médico o farmacéutico antes de tomar este medicamento.

Los estudios en animales han demostrado que Lyfnua puede pasar a la leche materna. No se puede descartar un riesgo para su bebé. Usted y su médico deben decidir de forma conjunta si tomar Lyfnua o elegir la lactancia.

Conducción y uso de máquinas

Es posible que se sienta mareado después de tomar Lyfnua. Si esto ocurre, no conduzca ni utilice herramientas o máquinas hasta que deje de sentirse mareado.

Lyfnua contiene sodio

Este medicamento contiene menos de 1 mmol de sodio (23 mg) por comprimido; esto es, esencialmente “exento de sodio”.

3. Cómo tomar Lyfnua

Siga exactamente las instrucciones de administración de este medicamento indicadas por su médico o farmacéutico. En caso de duda, consulte de nuevo a su médico o farmacéutico.

Qué cantidad tomar

La dosis recomendada de Lyfnua es:

  • un comprimido de 45 mg dos veces al día.

Adultos con problemas renales

Su médico puede cambiar la cantidad y la frecuencia con la que toma Lyfnua si:

  • tiene insuficiencia renal grave y no está en diálisis.

Como se toma

Trague el comprimido entero. No parta, machaque ni mastique el comprimido.

Puede tomar el comprimido con o sin alimentos.

Si toma más Lyfnua del que debe

Si toma demasiado Lyfnua, contacte con un médico o farmacéutico inmediatamente.

Si olvidó tomar Lyfnua

Si olvida una dosis, sáltese esa dosis y tome la siguiente dosis a la hora programada.

No tome una dosis doble para compensar las dosis olvidadas.

Si tiene cualquier otra duda sobre el uso de este medicamento, pregunte a su médico o farmacéutico.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Posibles efectos adversos

Al igual que todos los medicamentos, este medicamento puede producir efectos adversos, aunque no todas las personas los sufran.

Los posibles efectos adversos son:

Muy frecuentes (pueden afectar a más de 1 de cada 10 personas)

  • cambio en el sabor de las cosas (como sabor a: metálico, amargo o salado)
  • tener menos capacidad degustativa
  • pérdida del gusto

Frecuentes(pueden afectar a hasta 1 de cada 10 personas)

  • sensación de ganas de vomitar (náuseas)
  • sabor diferente de las cosas a como sabían antes
  • tos (empeoramiento, aumento)
  • boca seca
  • infección de las vías respiratorias superiores (una infección en la parte superior de las vías respiratorias, que incluye la nariz y la garganta)
  • diarrea
  • dolor en la boca o la garganta
  • tener menos hambre de lo habitual
  • sentirse mareado
  • dolor en la zona alta del abdomen (vientre)
  • indigestión
  • sensaciones inusuales en la boca (por ejemplo, hormigueo o sensación de picor)
  • pérdida de sensibilidad en la boca
  • aumento de la producción de saliva
  • insomnio (dificultad para dormir)
  • dolor de cabeza

Poco frecuentes(pueden afectar a hasta 1 de cada 100 personas)

  • piedras en la vejiga, en la orina o en el riñón

Comunicación de efectos adversos

Si experimenta cualquier tipo de efecto adverso, consulte a su médico o farmacéutico, incluso si se trata de posibles efectos adversos que no aparecen en este prospecto. También puede comunicarlos directamente a través del sistema nacional de notificación incluido en el Apéndice V. Mediante la comunicación de efectos adversos usted puede contribuir a proporcionar más información sobre la seguridad de este medicamento.

5. Conservación de Lyfnua

Mantener este medicamento fuera de la vista y del alcance de los niños.

No utilice este medicamento después de la fecha de caducidad que aparece en el blíster y la caja después de “CAD”. La fecha de caducidad es el último día del mes que se indica.

Este medicamento no requiere condiciones especiales de conservación.

No utilice este medicamento si observa que el envase está dañado o muestra signos de manipulación.

Los medicamentos no se deben tirar por los desagües ni a la basura. Pregunte a su farmacéutico cómo deshacerse de los envases y de los medicamentos que ya no necesita. De esta forma, ayudará a proteger el medio ambiente.

6. Contenido del envase e información adicional

Composición de Lyfnua

El principio activo es gefapixant. Cada comprimido recubierto con película contiene 45 mg de gefapixant (como citrato).

Los demás componentes son sílice (coloidal anhidra) (E 551), crospovidona (E 1202), hipromelosa (E 464), estearato de magnesio (E 470b), manitol (E 421), celulosa microcristalina (E 460), fumarato de estearilo y sodio. Los comprimidos están recubiertos con película con un material de recubrimiento que contiene los siguientes componentes: hipromelosa (E 464), dióxido de titanio (E 171), triacetina (E 1518) y óxido de hierro rojo (E 172). Los comprimidos están pulidos con cera de carnauba (E 903).

Aspecto del producto y contenido del envase

Lyfnua es un comprimido de color rosa, redondo y convexo, grabado con “777” en una cara y liso en la otra.

Lyfnua está disponible en blísteres de PVC/PE/PVdC de color blanco, opacos, con cubierta de lámina de aluminio de abertura a presión.

Lyfnua está disponible en envases de 28, 56 y 98 comprimidos recubiertos con película en blísteres no perforados (14 comprimidos por placa) y envases múltiples con 196 (2 envases de 98) comprimidos recubiertos con película en blísteres no perforados.

Puede que solamente estén comercializados algunos tamaños de envases.

Titular de la autorización de comercialización y responsable de la fabricación

Merck Sharp & Dohme B.V.

Waarderweg 39

2031 BN Haarlem

Países Bajos

Pueden solicitar más información respecto a este medicamento dirigiéndose al representante local del titular de la autorización de comercialización:

België/Belgique/Belgien

MSD Belgium

Tél/Tel: +32(0)27766211

[email protected]

Lietuva

UAB Merck Sharp & Dohme

Tel. +370 5 2780 247

[email protected]

Texto en idioma búlgaro mostrando nombre de empresa Merck Sharp & Dohme Bulgaria, teléfono y dirección de correo electrónico

Luxembourg/Luxemburg

MSD Belgium

Tél/Tel: +32(0)27766211

[email protected]

Ceská republika

Merck Sharp & Dohme s.r.o.

Tel: +420 233 010 111

[email protected]

Magyarország

MSD Pharma Hungary Kft.

Tel.: +36 1 888 5300

[email protected]

Danmark

MSD Danmark ApS

Tlf.: + 45 4482 4000

[email protected]

Malta

Merck Sharp & Dohme Cyprus Limited

Tel: 8007 4433 (+356 99917558)

[email protected]

Deutschland

MSD Sharp & Dohme GmbH

Tel.: +49 (0) 89 20 300 4500

[email protected]

Nederland

Merck Sharp & Dohme B.V.

Tel: 0800 9999000

(+31 23 5153153)

[email protected]

Eesti

Merck Sharp & Dohme OÜ

Tel: +372 614 4200

[email protected]

Norge

MSD (Norge) AS

Tlf: +47 32 20 73 00

[email protected]

Ελλ?δα

MSD Α.Φ.Ε.Ε.

Τηλ: +30 210 98 97 300

[email protected]

Österreich

Merck Sharp & Dohme Ges.m.b.H.

Tel: +43 (0) 1 26 044

[email protected]

España

Merck Sharp & Dohme de España, S.A.

Tel: +34 91 321 06 00

[email protected]

Polska

MSD Polska Sp. z o.o.

Tel: +48 22 549 51 00

[email protected]

France

MSD France

Tél: + 33 (0) 1 80 46 40 40

Portugal

Merck Sharp & Dohme, Lda

Tel: +351 21 4465700

[email protected]

Hrvatska

Merck Sharp & Dohme d.o.o.

Tel: + 385 1 6611 333

[email protected]

România

Merck Sharp & Dohme Romania S.R.L.

Tel: +40 21 529 29 00

[email protected]

Ireland

Merck Sharp & Dohme Ireland (Human Health) Limited

Tel: +353 (0)1 2998700

[email protected]

Slovenija

Merck Sharp & Dohme, inovativna zdravila d.o.o.

Tel: +386 1 520 4201

[email protected]

Ísland

Vistor ehf.

Sími: + 354 535 7000

Slovenskárepublika

Merck Sharp & Dohme, s. r. o.

Tel: +421 2 58282010

[email protected]

Italia

MSD Italia S.r.l.

Tel: 800 23 99 89 (+39 06 361911)

[email protected]

Suomi/Finland

MSD Finland Oy

Puh/Tel: +358 (0)9 804 650

[email protected]

Κ?προς

Merck Sharp & Dohme Cyprus Limited

Τηλ.: 800 00 673 (+357 22866700)

[email protected]

Sverige

Merck Sharp & Dohme (Sweden) AB

Tel: +46 77 5700488

[email protected]

Latvija

SIA Merck Sharp & Dohme Latvija

Tel: + 371 67025300

[email protected]

Fecha de la última revisión de este prospecto:

La información detallada de este medicamento está disponible en la página web de la Agencia Europea de Medicamentos: https://www.ema.europa.eu

Online doctors for LYFNUA 45 mg FILM-COATED TABLETS

Discuss questions about LYFNUA 45 mg FILM-COATED TABLETS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (17)
Doctor

Anastasiia Shalko

Family medicine 13 years exp.

Dr. Anastasiia Shalko is a general practitioner with a background in both paediatrics and general medicine. She graduated from Bogomolets National Medical University in Kyiv and completed her paediatric internship at the P.L. Shupyk National Medical Academy of Postgraduate Education. After working as a paediatrician in Kyiv, she relocated to Spain, where she has been practising general medicine since 2015, providing care for both adults and children.

Her work focuses on urgent, short-term medical concerns – situations where patients need quick guidance, symptom assessment and clear next steps. She helps people understand whether their symptoms require in-person evaluation, home management or a change in treatment. Common reasons for booking an online consultation include:

  • acute respiratory symptoms (cough, sore throat, runny nose, fever)
  • viral illnesses such as colds and seasonal infections
  • gastrointestinal complaints (nausea, diarrhoea, abdominal pain, gastroenteritis)
  • sudden changes in how a child or adult feels
  • questions about existing treatment and whether adjustments are needed
  • renewal of prescriptions when clinically appropriate
Dr. Shalko works specifically with urgent and short-term problems, providing practical recommendations and helping patients determine the safest next step. She explains symptoms clearly, guides patients through decision-making and offers straightforward medical advice for everyday acute issues.

She does not provide long-term management of chronic conditions, ongoing follow-up or comprehensive care plans for complex long-term illnesses. Her consultations are designed for acute symptoms, sudden concerns and situations where timely medical input is important.

With clinical experience in both paediatrics and general medicine, Dr. Shalko confidently supports adults and children. Her communication style is clear, simple and reassuring, helping patients feel informed and supported throughout the consultation.

Camera Book a video appointment
€50
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80
0.0 (0)
Doctor

Daniel Cichi

Family medicine 24 years exp.

Dr Daniel Cichi is a family medicine doctor with over 20 years of clinical experience. He provides online consultations for adults, supporting patients with acute symptoms, chronic conditions, and everyday health concerns that require timely medical guidance.

His background includes work in emergency care, ambulance services, and family medicine, which allows him to assess symptoms quickly, identify warning signs, and help patients choose the safest next steps – whether that means home care, treatment adjustment, or in-person evaluation.

Patients commonly consult Dr Daniel Cichi for:

  • acute symptoms: fever, infections, flu-like illness, cough, sore throat, shortness of breath;
  • chest discomfort, palpitations, dizziness, fatigue, and blood pressure concerns;
  • digestive problems: abdominal pain, nausea, diarrhoea, constipation, reflux;
  • muscle, joint, and back pain, minor injuries, post-traumatic symptoms;
  • chronic conditions: hypertension, diabetes, high cholesterol, thyroid disorders;
  • review and interpretation of lab tests, imaging reports, and medical documents;
  • medication review and treatment adjustment;
  • medical advice while travelling or living abroad;
  • second opinions and guidance on whether in-person care is needed.
Dr Cichi’s consultations are structured and practical. He focuses on clear explanations, risk assessment, and actionable recommendations, helping patients understand their symptoms and make informed decisions about their health.
Camera Book a video appointment
€55

Frequently Asked Questions

Is a prescription required for LYFNUA 45 mg FILM-COATED TABLETS?
LYFNUA 45 mg FILM-COATED TABLETS requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in LYFNUA 45 mg FILM-COATED TABLETS?
The active ingredient in LYFNUA 45 mg FILM-COATED TABLETS is gefapixant. This information helps identify medicines with the same composition but different brand names.
Who manufactures LYFNUA 45 mg FILM-COATED TABLETS?
LYFNUA 45 mg FILM-COATED TABLETS is manufactured by Merck Sharp & Dohme B.V.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of LYFNUA 45 mg FILM-COATED TABLETS online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether LYFNUA 45 mg FILM-COATED TABLETS is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to LYFNUA 45 mg FILM-COATED TABLETS?
Other medicines with the same active substance (gefapixant) include ANGITUSS 6mg/mL SYRUP, BISOLVON CALMATOS 2.13 mg/ml ORAL SOLUTION, BRONCHOSTOP NITE ORAL SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media